HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Woitge, H. W. Articles by Seibel, M. J. Search for Related Content PubMed PubMed Citation Articles by Woitge, H. W. Articles by Seibel, M. J. Related Collections Proteomics and Protein Markers Drug Monitoring and Toxicology Endocrinology and Metabolism

Short- and Long-Term Effects of Ibandronate Treatment on Bone Turnover in Paget Disease of Bone

Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Heidelberg, Bergheimerstrasse 58, D-69115 Heidelberg, Germany.
^a Author for correspondence. Fax 49-6221-564101; e-mail Markus_Seibel{at}med.uni-heidelberg.de

Background: In Paget disease of bone (PD), serum total alkaline phosphatase (TAP) is a valid marker of disease activity. The aim of the present longitudinal study was to compare TAP with new and potentially more specific markers of bone turnover in bisphosphonate-treated patients with PD.

Methods: Twenty patients with active PD were studied before and after treatment with 2 mg of intravenous ibandronate over a period of 12 months. TAP (by colorimetry), serum bone-specific alkaline phosphatase (BAP; by enzyme immunoassay), serum osteocalcin (OC; by ELISA), serum bone sialoprotein (BSP; by RIA), and urinary total pyridinoline (PYD; by HPLC) and deoxypyridinoline (DPD; by HPLC) were measured as markers of bone turnover.

Results: Before treatment, TAP, BAP, and BSP were increased in all 20 patients, whereas OC was increased in 10, PYD in 13, and DPD in 15 patients. Three months post treatment, nine patients showed normalized TAP values, and a 25% re-increase (i.e., relapse) was observed in all patients after 12 months. A normalization of BAP was achieved in six patients only. No significant changes were found for OC. BSP was decreased significantly at 24 h, and DPD at 48 h post treatment. A normalization of BSP was found in 8, of PYD in 18, and of DPD in 16 cases. Both PYD and DPD increased significantly from 9 months post treatment onward.

Conclusions: Most markers of bone turnover show similar long-term changes after treatment of active PD with ibandronate. With regard to cost-effectiveness and assay performance, TAP remains the marker of choice in therapeutic monitoring of PD. However, more specific markers may improve the biochemical assessment of PD in certain situations.

The following articles in journals at HighWire Press have cited this article:

				M. E. Kraenzlin, C. A. Kraenzlin, C. Meier, C. Giunta, and B. Steinmann Automated HPLC Assay for Urinary Collagen Cross-links: Effect of Age, Menopause, and Metabolic Bone Diseases Clin. Chem., September 1, 2008; 54(9): 1546 - 1553. [Abstract] [Full Text] [PDF]

				J. Barrett, E. Worth, F. Bauss, and S. Epstein Ibandronate: A Clinical Pharmacological and Pharmacokinetic Update J. Clin. Pharmacol., September 1, 2004; 44(9): 951 - 965. [Abstract] [Full Text] [PDF]

				H. W. Woitge, E. Horn, A. V. Keck, B. Auler, M. J. Seibel, and M. Pecherstorfer Biochemical Markers of Bone Formation in Patients with Plasma Cell Dyscrasias and Benign Osteoporosis Clin. Chem., April 1, 2001; 47(4): 686 - 693. [Abstract] [Full Text] [PDF]